Skip to content

Session 151: RBM in Space

Loading image:
Donate

At the International IVF Initiative, we are committed to providing free access to our educational sessions, webinars, and resources for professionals and individuals passionate about advancing reproductive medicine. We believe that cost should never be a barrier to knowledge and collaboration. By contributing, you’re ensuring that valuable educational resources, expert insights, and collaborative opportunities remain open to all without financial barriers. Together, we can continue to foster a global community dedicated to innovation and excellence in the field of IVF.

Donate
Your Donation
Regular price $10.00

Thank you!

Session 151: Reproductive BioMedicine in Space III

Tuesday 13 May, 3pm EST / 8pm UK / 9pm CET

Moderators: 

Prof. Virginia Wotring
Dr. Fathi Karouia
Dr. Christopher E Mason
Giles Palmer

Panelist: Dr. Blair T Stocks

Presenters:
Dr. Begum Mathyk: Female reproductive health in space

Dr. Jeffrey Jones: male reproductive system impacted by
space.

Dr. Paul Root Wolpe on Ethical considerations
associated with spaceflight.

 

Register:

TBA

Prof. Virginia Wotring


Virginia Wotring has been using her training in biochemistry and  PhD in physiology & pharmacology (Saint Louis University, USA) to study the actions of medications used during spaceflight missions. 
She is Chief Academic Officer and Professor at the International Space University in Strasbourg France. She had held management positions such as Deputy Director and Chief Scientist of the NASA-funded Translational Research Institute for Space Health, however she prefers doing science to managing it. So Virginia Wotring studies effects of the spaceflight environment on physiology, especially those that may change how medications work.

 


Dr. Fathi Karouia

Dr. Fathi Karouia is a seasoned leader in space life sciences with over 20 years of experience advancing biomedical research in space. He has led more than 35 successful experiments aboard the International Space Station (ISS), exploring how microgravity and spaceflight affect biological systems. His research focuses on human health, systems biology, and the development of innovative countermeasures for long-duration missions. As the In-Space Commercialization Lead at BioServe Space Technologies, Dr. Karouia pioneers strategies to leverage microgravity for biomanufacturing applications, including the expansion of hematopoietic stem cells to treat blood cancer patients on Earth. He actively supports startup ventures, drives commercialization pathways, and contributes to the new Low Earth Orbit (LEO) economy. With a multidisciplinary academic background and deep involvement in international space initiatives, he is dedicated to translating space-based science into tangible solutions that benefit humanity. Dr. Karouia also serves as a mentor, speaker, and advocate for diversity in space research.

Dr. Fathi Karouia is a seasoned leader in space life sciences with over 20 years of experience advancing biomedical research in space. He has led more than 35 successful experiments aboard the International Space Station (ISS), exploring how microgravity and spaceflight affect biological systems. His research focuses on human health, systems biology, and the development of innovative countermeasures for long-duration missions. As the In-Space Commercialization Lead at BioServe Space Technologies, Dr. Karouia pioneers strategies to leverage microgravity for biomanufacturing applications, including the expansion of hematopoietic stem cells to treat blood cancer patients on Earth. He actively supports startup ventures, drives commercialization pathways, and contributes to the new Low Earth Orbit (LEO) economy. With a multidisciplinary academic background and deep involvement in international space initiatives, he is dedicated to translating space-based science into tangible solutions that benefit humanity. Dr. Karouia also serves as a mentor, speaker, and advocate for diversity in space research.

.

Dr. Christopher E Mason

Dr. Mason is the WorldQuant Professor of Genomics and Computational Biomedicine at Weill Cornell Medicine, where he also directs the Initiative for Quantitative Prediction and the Cornell Aerospace Medicine Biobank. With a background that spans a dual B.S. in Genetics and Biochemistry, a Ph.D. in Genetics from Yale, and a Clinical Genetics Fellowship at Yale Medical School, his career reflects a deep commitment to both scientific innovation and ethical inquiry—he was also Visiting Fellow of Genomics, Ethics, and Law at Yale Law School. Dr. Mason’s, work that has led to over 350 peer-reviewed papers, five patents, diagnostics innovations, and the founding of multiple biotech companies and non-profits. He also holds affiliate positions at the New York Genome Center, Yale Law School, and the Consortium for Space Genetics at Harvard Medical School. Dr. Mason is the founder of the MetaSUB Consortium and the author of The Next 500 Years and The Age of Prediction. 


Back to top